Recordati (RCDTF) Upgraded by Zacks Investment Research to “Hold”

Share on StockTwits

Recordati (OTCMKTS:RCDTF) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

According to Zacks, “Recordati S.p.A. is a pharmaceutical company. It engaged in the research, development, manufacturing and marketing of pharmaceuticals for rare disease treatments. The company operates primarily in Russia, Turkey, North Africa and United States of America. Recordati S.p.A. is headquartered in Milan, Italy. “

RCDTF stock opened at $34.70 on Thursday. The company has a market capitalization of $7.26 billion, a P/E ratio of 21.96, a P/E/G ratio of 2.50 and a beta of 0.06. Recordati has a 52 week low of $34.70 and a 52 week high of $34.87.

About Recordati

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals in Europe, the Middle East, Africa, the United States, Canada, and internationally. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, cosmetics, dermatology, dietary supplements, gynecology and obstetrics, medical devices, musculo-skeletal disorders and analgesia, over the counter/non-prescription pharmaceuticals, urology, allergy, anti-infectives, central nervous system, endocrinology, gastrointestinal, nutrition and related products, immune-suppressants, pain management/inflammation, generics, pneumology, antipyretics and cold preparations, endocrinology, oncology, respiratory, and radio contrast agent, as well as ear, nose, and throat.

Featured Story: Bear Market

Get a free copy of the Zacks research report on Recordati (RCDTF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Recordati Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recordati and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

BLOC.MONEY  Trading Down 0.4% Over Last Week
BLOC.MONEY Trading Down 0.4% Over Last Week
Kleros  Tops 1-Day Trading Volume of $1,549.00
Kleros Tops 1-Day Trading Volume of $1,549.00
Adamis Pharmaceuticals Corp  CFO Robert O. Hopkins Sells 8,900 Shares
Adamis Pharmaceuticals Corp CFO Robert O. Hopkins Sells 8,900 Shares
Robert P. Jornayvaz III Acquires 13,900 Shares of Intrepid Potash, Inc.  Stock
Robert P. Jornayvaz III Acquires 13,900 Shares of Intrepid Potash, Inc. Stock
Michael Arntz Sells 3,055 Shares of Smartsheet Inc  Stock
Michael Arntz Sells 3,055 Shares of Smartsheet Inc Stock
Investors Sell Conagra Brands  on Strength
Investors Sell Conagra Brands on Strength


 
© 2006-2019 Zolmax.